IVIG FOR RECURRENT MISCARRIAGE: RCT

IVIG 治疗复发性流产：RCT

• 批准号: 7378638
• 负责人: MARY D STEPHENSON
• 金额: $ 2.88万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-18 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378638
• 关键词: birth; clinical trials; immune response; pharmacokinetics; pregnancy; spontaneous abortion

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this clinical trial are twofold: 1. to evaluate the efficacy of IVIG in improving the live birth rate in couples with unexplained secondary recurrent miscarriage. 2. To characterize and compare pharmacokinetic and pharmacodynamic parameters for IVIG pre-conceptually and in the 1st and 2nd trimesters of pregnancy for determination of the best IVIG dosing strategy. With the completion of this project, further understanding of the maternal immune response to pregnancy will be achieved.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项临床试验的目的有两个：1.评价静脉注射免疫球蛋白在提高原因不明继发性反复流产夫妇活产率方面的效果。2.比较IVIG孕前、孕期和孕中期的药代动力学和药效学参数，以确定IVIG的最佳给药方案。随着该项目的完成，将进一步了解孕妇对怀孕的免疫反应。